Replies to post #197698 on Amarin Corp Plc (AMRN)

[louieblouie]

were Hikma and Teva challenging the patent(s) on the same grounds or for different reasons?

[MedResCollab]

VuBru,

If a settlement occurs you all are not going to like the terms. But it’s very unlikely to occur. The issue is Vacepa = Amarin. That is all Amarin is. Amarin will only settle for a deal similar to Teva’s. And in our view Teva only settled because they knew DRL/Hikma would not, and would likely win, and thus they received millions, saved millions (and time), and only lost a handful of potential months selling Vascepa due to 180-day exclusivity. And at the time of the settlement REDUCE-IT data was unknown, and the trial deemed unlikely to succeed, and Teva already had a large stake in the TG>500 mg/dL market anyway. And Teva was (and is) facing financial difficulties.

The Teva settlement should not inspire confidence, it should unsettle you all as AMRN bulls. It was just optics for Amarin, and if anything reveals their insecurity in their own IP.